Completed PHASE1 INTERVENTIONAL 19-arm NCT04047862

Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors

Phase 1/1b Study Investigating Safety, Tolerability, PK and Antitumor Activity of Anti-TIGIT Monoclonal Antibody BGB-A1217 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors

Sponsor: BeiGene

Conditions Locally Advanced and Metastatic Solid Tumors

Interventions 5fluorouracil Capecitabine Carboplatin Cisplatin Etoposide Nab paclitaxel Ociperlimab Oxaliplatin Paclitaxel Pemetrexed Tislelizumab

Updated 25 times since 2019 Last updated: Aug 4, 2025 Started: Aug 15, 2019 Primary completion: Aug 7, 2024 Completion: Aug 7, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Locally Advanced and Metastatic Solid Tumors, this trial is completed. The trial is conducted by BeiGene and has accumulated 25 data snapshots since 2019. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

25 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Feb 2025 — Sep 2025 [monthly]

Completed PHASE1
Dec 2024 — Feb 2025 [monthly]

Completed PHASE1
Oct 2024 — Dec 2024 [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed
Sep 2024 — Oct 2024 [monthly]

Active Not Recruiting PHASE1

▶ Show 20 earlier versions

Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE1
Apr 2024 — Jul 2024 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting
Feb 2024 — Apr 2024 [monthly]

Recruiting PHASE1
Jan 2024 — Feb 2024 [monthly]

Recruiting PHASE1
Dec 2023 — Jan 2024 [monthly]

Recruiting PHASE1
Sep 2023 — Dec 2023 [monthly]

Recruiting PHASE1
Aug 2023 — Sep 2023 [monthly]

Recruiting PHASE1
Jun 2023 — Aug 2023 [monthly]

Recruiting PHASE1
Mar 2023 — Jun 2023 [monthly]

Recruiting PHASE1
Jun 2022 — Mar 2023 [monthly]

Recruiting PHASE1
Dec 2021 — Jun 2022 [monthly]

Recruiting PHASE1
Oct 2021 — Dec 2021 [monthly]

Recruiting PHASE1
May 2021 — Oct 2021 [monthly]

Recruiting PHASE1
Jan 2021 — May 2021 [monthly]

Recruiting PHASE1
Dec 2020 — Jan 2021 [monthly]

Recruiting PHASE1
Nov 2020 — Dec 2020 [monthly]

Recruiting PHASE1
Dec 2019 — Nov 2020 [monthly]

Recruiting PHASE1
Nov 2019 — Dec 2019 [monthly]

Recruiting PHASE1
Oct 2019 — Nov 2019 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Sep 2019 — Oct 2019 [monthly]

Not Yet Recruiting PHASE1

First recorded

Aug 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

BeiGene

Data source: BeiGene

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Auckland, New Zealand , Beijing, China , Bendigo, Australia , Benowa, Australia , Blacktown, Australia , Camperdown, Australia , Changchun, China , Changsha, China , Chengdu, China , Chongqing, China and 43 more locations